全文获取类型
收费全文 | 1276篇 |
免费 | 85篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 29篇 |
妇产科学 | 23篇 |
基础医学 | 178篇 |
口腔科学 | 11篇 |
临床医学 | 109篇 |
内科学 | 370篇 |
皮肤病学 | 97篇 |
神经病学 | 78篇 |
特种医学 | 30篇 |
外科学 | 157篇 |
综合类 | 5篇 |
预防医学 | 103篇 |
眼科学 | 4篇 |
药学 | 85篇 |
中国医学 | 1篇 |
肿瘤学 | 80篇 |
出版年
2023年 | 6篇 |
2022年 | 21篇 |
2021年 | 42篇 |
2020年 | 23篇 |
2019年 | 37篇 |
2018年 | 45篇 |
2017年 | 32篇 |
2016年 | 45篇 |
2015年 | 43篇 |
2014年 | 35篇 |
2013年 | 40篇 |
2012年 | 90篇 |
2011年 | 67篇 |
2010年 | 42篇 |
2009年 | 40篇 |
2008年 | 57篇 |
2007年 | 77篇 |
2006年 | 67篇 |
2005年 | 55篇 |
2004年 | 58篇 |
2003年 | 48篇 |
2002年 | 53篇 |
2001年 | 22篇 |
2000年 | 31篇 |
1999年 | 25篇 |
1998年 | 13篇 |
1997年 | 6篇 |
1996年 | 11篇 |
1995年 | 7篇 |
1994年 | 5篇 |
1993年 | 5篇 |
1992年 | 23篇 |
1991年 | 23篇 |
1990年 | 15篇 |
1989年 | 18篇 |
1988年 | 21篇 |
1987年 | 15篇 |
1986年 | 12篇 |
1985年 | 19篇 |
1984年 | 12篇 |
1983年 | 14篇 |
1980年 | 5篇 |
1979年 | 4篇 |
1978年 | 6篇 |
1973年 | 3篇 |
1969年 | 3篇 |
1967年 | 4篇 |
1966年 | 4篇 |
1965年 | 4篇 |
1932年 | 2篇 |
排序方式: 共有1370条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Rigatelli Gianluca; Cardaioli Paolo; Giordan Massimo; Roncon Loris 《European heart journal》2007,28(1):51
A 65-year-old hypertensive man with shortness of breath andatypical thoracic pain underwent coronary angiography for 相似文献
6.
7.
F. V. Costa C. Borghi A. Mussi E. Ambrosioni 《European journal of clinical pharmacology》1986,30(2):145-150
Summary The long-term efficacy of a new vasodilator, cadralazine (ISF 2469), and chlorthalidone have been compared in 20 hypertensive patients not adequately controlled by atenolol. After 4 weeks of treatment with atenolol 100 mg once daily, patients whose diastolic blood pressure was >95 mmHg were randomly divided into two groups to receive in addition to atenolol, either cadralazine 15 mg once daily or chlorthalidone 25 mg once daily. Both treatments were administered for 6 months. At the end of treatment with atenolol and after 3 and 6 months of combination therapy, blood pressure and heart rate were measured at rest and during bicycle exercise 24 h after the last dose. Compared to atenolol alone, both cadralazine and chlorthalidone caused a significant and similar reduction in resting blood pressure. Both groups showed an increase in diastolic blood pressure during exercise while receiving atenolol alone. The addition of chlorthalidone did not modify the pressor response to exercise, whereas patients taking cadralazine had a decrease in exercise diastolic blood pressure, which was fully evident after 6 months of therapy. The reduction in exercise diastolic blood pressure induced by cadralazine was proportional to the increase in exercise heart rate, suggesting a fall in peripheral vascular resistance. Chlorthalidone caused a significant increase in serum glucose and uric acid and a decrease in K+, whereas no change was observed during cadralazine It is concluded that cadralazine given once a day with atenolol has the same efficacy in controlling blood pressure at rest as the combination of atenolol and chlorthalidone, and in addition it improves the pressor response to dynamic exercise and does not cause unwanted metabolic effects. 相似文献
8.
9.
10.
C Borghi C Magelli S Boschi F V Costa M Capelli E Varani B Magnani E Ambrosioni 《Journal of clinical pharmacology》1989,29(12):1077-1082
In 14 patients with congestive heart failure (CHF) of various grade (NYHA class 2-4) the effects of zofenopril calcium (SQ 26,991) on blood pressure and forearm circulation were studied by venous occlusion plethysmography. Changes in plasma renin activity (PRA), aldosterone, Atrial natriuretic factor (ANF) and arginine-vasopressin (AVP) were also measured. Two hours after oral administration of 7.5 mg of zofenopril we observed a decrease in blood pressure, heart rate, and forearm vascular resistance along with an increase in venous distensibility. Zofenopril also decreased ANP levels in a manner directly related to peripheral venodilatation (r = .64; P less than .05) and modified arginine-vasopressin (AVP) proportionally to the fall in blood pressure observed in response to drug administration (%SBP/%AVP: r = .64, P less than .05; %DBP/%AVP: r = .67, P less than .05). Hemodynamic and humoral responses to zofenopril occurred without any significant unwanted adverse reaction, even in patients with greater pressor reduction. We conclude that oral acute zofenopril administration, in patients with congestive heart failure, causes an arterial and venous forearm vasodilatation which is probably involved in the acute changes in plasma levels of ANF and AVP observed after drug administration. 相似文献